Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Foghorn Therapeutics Inc. (FHTX) Revenue by Segment & Business Profile

Oncology drug candidates for cancer patients was 100.0% of Foghorn Therapeutics Inc.'s revenue, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

FHTXFoghorn Therapeutics Inc.Follow FHTX — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
118.8M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
10 Nov, in 17 days

What the company does

Foghorn Therapeutics Inc. is a drug manufacturers - general company in the healthcare sector. Trailing twelve-month revenue: $36.7 million as of 2026-06-30.

Roles we read

from the filings, not the sector label
  • Large-cap pharmaceuticals

Foghorn Therapeutics Inc. — questions

What does Foghorn Therapeutics Inc. do?
Foghorn Therapeutics Inc. is a drug manufacturers - general company in the healthcare sector. Trailing twelve-month revenue: $36.7 million as of 2026-06-30.
How does Foghorn Therapeutics Inc. make money?
By the lines it reports in its SEC filings: Oncology drug candidates for cancer patients 100.0% of revenue.

Every figure on this page comes from Foghorn Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.